WO2013123049A1 - Dispositif de génie tissulaire et construction de derme vascularisé - Google Patents

Dispositif de génie tissulaire et construction de derme vascularisé Download PDF

Info

Publication number
WO2013123049A1
WO2013123049A1 PCT/US2013/025938 US2013025938W WO2013123049A1 WO 2013123049 A1 WO2013123049 A1 WO 2013123049A1 US 2013025938 W US2013025938 W US 2013025938W WO 2013123049 A1 WO2013123049 A1 WO 2013123049A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
fibrin
rendering
program instructions
construct
Prior art date
Application number
PCT/US2013/025938
Other languages
English (en)
Inventor
Thomas Boland
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to EP13749912.5A priority Critical patent/EP2814529A4/fr
Priority to CA2864665A priority patent/CA2864665A1/fr
Priority to AU2013221660A priority patent/AU2013221660A1/en
Publication of WO2013123049A1 publication Critical patent/WO2013123049A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B29C64/106—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
    • B29C64/112—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Definitions

  • the disclosed embodiments relate to cell printing technology and tissue engineering.
  • the disclosed embodiments further relate to a vascularized dermis produced using cell printing techniques.
  • the disclosed embodiments also relate to an intraoperative adipose tissue engineering device.
  • Engineered tissues can be supported by the diffusion of nutrients from host vasculature. When the thickness of engineered tissue, however, exceeds 150-200 ⁇ m, the tissue's depth surpasses the oxygen diffusion limitation. Therefore, functional vasculatures within engineered tissues must be created to both supply cells with oxygen and nutrients and remove the waste products.
  • An inkjet printing method, system, and computer-usable tangible storage device to print cells and biomaterials for three-dimensional cellular scaffolds are disclosed.
  • the process simultaneously deposits living cells, nutrients, growth factors, therapeutic drugs along with biomaterial scaffolds at the right time and location.
  • This technology can also be used for the microvasculature fabrication using appropriate human microvascular endothelial cells and fibrin to form the microvasculature.
  • human microvascular endothelial cells in conjunction with the fibrin the cells aligned themselves inside the channels and proliferated to form confluent linings.
  • the 3D tubular structure was also found in the printed patterns.
  • Simultaneously printing biological materials to form a three-dimensional cellular scaffold promotes human microvascular endothelial cell proliferation and microvasculature formation.
  • FIG. 1 illustrates a schematic view of a data-processing system in which an embodiment may be implemented, in accordance with the disclosed embodiments;
  • FIG. 2 illustrates a schematic view of a software system including an operating system, application software, and a user interface, in accordance with the disclosed embodiments;
  • FIG. 3 illustrates a graphical representation of a network of data-processing systems, in accordance with the disclosed embodiments
  • FIG. 4 illustrates a schematic illustration of simultaneous deposition of HMVEC and fibrin into a fibrin channel scaffold orifice via a modified thermal inkjet printer, in accordance with the disclosed embodiments
  • FIG. 5 illustrates a table of selected fibronigen and thrombin concentration tests for fibrin polymerization via printing, in accordance with the disclosed embodiments
  • FIG. 6 illustrates pictorial illustrations of printed fibrin scaffold using a modified thermal inkjet printer, in accordance with the disclosed embodiments
  • FIG. 7 illustrates pictorial illustrations of scanning electron microscope images of printed fibrin fiber, in accordance with the disclosed embodiments.
  • FIG. 8 illustrates pictorial illustrations of magnified, printed human microvasculature from a printed pattern, in accordance with the disclosed embodiments;
  • FIG. 9 illustrates pictorial illustrations of the channel structure of cultured and printed microvasculature, in accordance with the disclosed embodiments.
  • FIG. 10 illustrates pictorial illustrations of the integrity of the printed human microvasculature, in accordance with the disclosed embodiments.
  • FIG. 11 illustrates a pictorial illustration of an intraoperative adipose tissue engineering device, in accordance with the disclosed embodiments.
  • FIGS. 1-3 are provided as exemplary diagrams of data-processing environments in which embodiments of the present invention may be implemented. It should be appreciated that FIGS. 1-3 are only exemplary and are not intended to assert or imply any limitation with regard to the environments in which aspects or embodiments of the disclosed embodiments may be implemented. Many modifications to the depicted environments may be made without departing from the spirit and scope of the present invention.
  • FIG. 1 illustrates a schematic view of a data-processing system in which an embodiment may be implemented.
  • the disclosed embodiments may be implemented in the context of a data-processing system 100 comprising, for example, a central processor 101, a main memory 102, an input/output controller 103, a keyboard 104, a pointing device 105 (e.g., mouse, track ball, pen device, or the like), a display device 106, and a mass storage 107 (e.g., hard disk).
  • Additional input/output devices such as a rendering device 108 (e.g., printer, scanner, fax machine, etc), for example, may be associated with the data-processing system 100 as desired.
  • a rendering device 108 e.g., printer, scanner, fax machine, etc
  • the various components of data-processing system 100 communicate electronically through a system bus 110 or similar architecture.
  • the system bus 110 may be a subsystem that transfers data between, for example, computer components within data-processing system 100 or to and from other data-processing devices, components, computers, etc.
  • FIG. 2 illustrates a computer software system 150 for directing the operation of the data-processing system 100 depicted in FIG. 1 , in accordance with the disclosed embodiments.
  • Software application cell printing module 152 stored in main memory 102 and on mass storage 107, generally includes a kernel or operating system 151 and a shell or interface 153.
  • One or more application programs, such as software application module 152 may be "loaded” (i.e., transferred from mass storage 107 into the main memory 102) for execution by the data-processing system 100.
  • the data- processing system 100 receives user commands and data through user interface 153; these inputs may then be acted upon by the data-processing system 100 in accordance with instructions from operating module 151 and/or software application module 152.
  • program modules include, but are not limited to, routines, subroutines, software applications, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types and instructions.
  • program modules include, but are not limited to, routines, subroutines, software applications, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types and instructions.
  • program modules include, but are not limited to, routines, subroutines, software applications, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types and instructions.
  • program modules include, but are not limited to, routines, subroutines, software applications, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types and instructions.
  • program modules include, but are not limited to, routines, subroutines, software applications, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types and instructions.
  • program modules include, but are not limited to, routines, sub
  • module may refer to a collection of routines and data structures that perform a particular task or implements a particular abstract data type. Modules may be composed of two parts: an interface, which lists the constants, data types, variable, and routines that can be accessed by other modules or routines; and an implementation, which is typically private (accessible only to that module) and which includes source code that actually implements the routines in the module.
  • the term module may also simply refer to an application such as a computer program designed to assist in the performance of a specific task such as word processing, accounting, inventory management, etc.
  • Such a module may also constitute a software application such as a "plug-in.”
  • plug-in refers generally to a computer program that interacts with a host application (e.g., a Web browser) to provide a certain, usually very specific, function "on demand.”
  • host application e.g., a Web browser
  • plug-in module and “module” may be utilized interchangeably to refer to the same component or application.
  • the interface 153 which is preferably a graphical user interface (GUI), can serve to display results, whereupon a user may supply additional inputs or terminate a particular session.
  • operating system 151 and interface 153 can be implemented in the context of a "Windows ® " system. It can be appreciated, of course, that other types of operating systems and interfaces may be alternatively utilized. For example, rather than a traditional "Windows ® " system, other operation systems such as, for example, LINUX ® may also be employed with respect to operating system 151 and interface 153.
  • the software application module 152 can include a virtual card plug-in module for automatically storing and distributing contact information over a network.
  • the virtual card plug-in module updates contact information with respect to a social and business networking system.
  • Software application module 152 can include instructions such as the various operations described herein with respect to the various components and modules.
  • virtual refers generally to something that is created, simulated, and/or carried on by means of a computer or computer network or other data-processing system.
  • FIG. 3 illustrates a pictorial illustration 200 of a rendering device coupled to a data-processing apparatus through a network, in accordance with the disclosed embodiments.
  • FIG. 3 is provided as an exemplary diagram of data processing environments in which embodiments of the present invention can be implemented. It should be appreciated that FIG. 3 is only exemplary and is not intended to assert or imply any limitation with regard to the environments in which aspects or embodiments of the present invention can be implemented. Many modifications to the depicted environments can be made without departing from the spirit and scope of the present invention.
  • system 200 includes a rendering device 240 that communicates with a data-processing system 210 through a network 235.
  • the data- processing system 210 can be, for example, a personal computer or other computing device, and generally includes a central processor 220, a display device 215, a keyboard 231, and a pointing device 230 (e.g., mouse, track ball, pen device, or the like).
  • the rendering device 240 may communicate directly with the data-processing system 210, rather than through a network such as, for example, network 235.
  • the network 235 can be coupled to a database 285.
  • rendering device may refer to an apparatus or system such as a printer, scanner, fax machine, copy machine, etc., and/or a combination thereof.
  • rendering device 240 is capable of multiple rendering functions such as printing, copying, scanning, faxing, etc.
  • rendering device 240 can be implemented with a single rendering function such as printing.
  • rendering device 240 can be configured to provide multiple rendering functions, such as scanning, faxing, printing and copying.
  • the data-processing system 210 can communicate with the rendering device 240 through, for example, a computer network 235 or other networking configuration.
  • Network 235 may employ any network topology, transmission medium, or network protocol.
  • Network 235 may include connections, such as wire, wireless communication links, or fiber optic cables.
  • the rendering device 240 includes a user interface 245, such as a panel menu.
  • the panel menu can be employed to select features and enter other data in the rendering device 240.
  • Such interfaces may include, for example, touch screens having touch activated keys for navigating through an option menu or the like.
  • a rendering device driver program can be installed on the data-processing system 210 and can reside on the host device's hard drive 250.
  • the rendering device driver program can be activated through an application interface so that a user may generate a rendering job with the driver for processing by the rendering device 240.
  • the data-processing system 210 also includes a GUI 225 for communicating rendering device features for processing, for example, the rendering job to a user and accepting the user's selection of available rendering device features.
  • the user interface 225 displays information and receives data through device display and/or the keyboard/mouse combination.
  • the interface 225 also serves to display results, whereupon the user may supply additional inputs or terminate a given session.
  • the data-processing system 210 can be, for example, any computing device capable of being integrated within a network, such as a PDA, personal computer, cellular telephone, mobile communications device, tablet device, point-of-sale terminal, server, etc.
  • the user interface as utilized herein generally refers to a type of environment that represents programs, files, options and so forth by means of graphically displayed icons, menus, and dialog boxes on a screen.
  • the input device of the rendering device 240 can comprise a local user interface, such as a touch-screen display or separate keypad and display or a memory fob or the like as discussed above.
  • the input device can be a wireless port that receives a wireless signal containing constraint data from a portable device.
  • the wireless signal can be an infrared or electromagnetic signal.
  • a system administrator may input constraint data through the local user interface by manipulating the touch screen, keypad, or communicating via wireless messages through the wireless port.
  • the administrator's portable device that communicates wirelessly can be a personal digital assistant (PDA), or the like, as noted above.
  • PDA personal digital assistant
  • the rendering device 240 can comprise an inkjet printing application using commercially available inkjet printers to print cells and biomaterials for three dimensional cellular scaffolds is disclosed.
  • Standard HP ® and Canon ® desktop inkjet printers can be modified to perform cell printing.
  • Organ printing defined as computer-aided inkjet based tissue engineering constructs 3D structures with living biological elements. An important advantage of this process is the ability to simultaneously deposit living cells, nutrients, growth factors, therapeutic drugs along with biomaterial scaffolds at the right time and location. This technology can also be used for the microvasculature fabrication using appropriate biomaterials and cells.
  • Cell printing technology can be used to reproduce damaged tissue using inkjet printing, a non-contact printing technique.
  • Inkjet printers have the ability to reproduce data on a substrate with tiny ink drops.
  • Drop-on-demand printing refers to ejected ink drops in specific locations to create the images on the substrate.
  • An inkjet printer has high operating frequency, high orifice density, integrated power, and interconnected electronics.
  • thermal inkjet printers small air bubbles are created by heating ink. The bubbles then collapse to provide the pressure pulse to eject a very tiny drop of ink out of the nozzle. The current pulse lasts a few microseconds and raises the plate temperature as high as 300°C.
  • a modified Hewlett-Packard ® Deskjet 500 thermal inkjet printer can be used to simultaneously deposit human microvascular endothelial cells and fibrin to form the microvasculature. It is understood that other printer models can be used in accordance with the disclosed embodiments.
  • HP ® Deskjet 500 inkjet printer has a droplet volume of 130 pL. There are 50 firing nozzles on the printer head and the actual heating occurs in a 10-MS pulse. The energy supplied during the printing process is transferred into kinetic energy and heating of the ink drop.
  • HMVEC Human microvascular endothelial cells
  • fibrin can be utilized as bio- ink for microvasculature construction.
  • FIG. 4 illustrates a schematic illustration 250 of simultaneous deposition of HMVEC 251 and fibrin 257 into a fibrin channel scaffold orifice 254 via a modified thermal inkjet printer, in accordance with the disclosed embodiments.
  • bio-ink 252 e.g., thrombin with Ca 2+
  • the cells in the bio-ink 252 are deposited into the scaffold simultaneously with a fibrin channel fabrication.
  • the printed cells are aligned inside the fibrin channel 253, thereafter ready for cell proliferation.
  • fibrin 257 is utilized in tissue engineering to engineer tissues with skeletal muscle cells, smooth muscle cells, and chondrocytes. Fibrin 257 plays a significant role in natural wound healing to promote cell migration, proliferation, and matrix synthesis through the incorporation of the transforming growth factor ⁇ and platelet-derived growth factors. Fibrin 257 can be produced from the patients' own blood and used as an autologous scaffold for tissue engineering. Polymerized at room temperature using fibrinogen and thrombin 252 solutions, fibrin gel has been widely used as sealant and adhesive during surgery, while fibrin glue is used as skin graft and tissue-engineered skin replacement. [0045] Micron-sized fibrin channels can be fabricated using a drop-on-demand polymerization.
  • This printing technique uses aqueous processes that have been shown to induce little, if any, damage to cells.
  • the cells aligned themselves inside the channels and proliferated to form confluent linings.
  • the three dimensional tubular structure was also found in the printed patterns.
  • a combined simultaneous cell and scaffold printing can promote HMVEC 251 proliferation and microvasculature formation.
  • MCDB 131 medium, fetal bovine serum, penicillin and streptomycin, sodium bicarbonate, L-glutamine, hydrocortisone, human recombinant epidermal growth factor, heparin, Dulbecco's phosphate buffered saline solution (DPBS), trypsin-EDTA, fibrinogen from bovine plasma, thrombin from bovine plasma were from Sigma Chemicals ® (St. Louis, MO, USA). Live/Dead Viability/Cytotoxicity Kit for mammalian cells was from Invitrogen ® (Carlsbad, CA, USA). IEC Centra-8R centrifuge was from International Equipment Company ® (Needham, MA, USA).
  • Microprocessor controlled 280 series water bath was from Precision Scientific ® (Winchester, VA, USA). Glass microscope cover slips and 35 mm tissue culture Petri dishes were from Fisher Scientific (Pittsburgh, PA, USA).
  • HP ® DeskJet 500 inkjet printer and HP 51626A black ink cartridges were from Hewlett-Packard ® (Palo Alto, CA, USA).
  • Advanced Micro Osmometer (Model 3300) was from Advanced Instruments, Inc. ® (Norwood, MA, USA).
  • Zeiss Axiovert S100 UV microscope and Zeiss LSM 510 laser scanning microscope were from Carl Zeiss ® (Minneapolis, MN, USA).
  • Electromechanical testing system was from MTS System Corporation ® (Eden Prairie, MN, USA).
  • Hummer 6.2 sputter coater was from Anatech Ltd. ® (Hayward, CA, USA).
  • Hitachi ® S4700N field emission scanning electron microscope was from Hitachi ® (Tokyo,
  • fibrin gel polymerizations were conducted with various combinations of fibrinogen, thrombin, and Ca 2+ concentrations (as illustrated in FIG. 5).
  • the appropriate concentrations of thrombin and fibrinogen solutions for optimum polymerization result were prepared.
  • the thrombin solution was made using 50 unit/ml thrombin and 80 mM Ca 2+ in 1 x DPBS.
  • the concentration of fibrinogen is 60 mg/ml in distilled water. Both solutions were filter sterilized.
  • FIG. 5 illustrates a table 300 of selected fibronigen and thrombin concentration tests for fibrin polymerization via printing, in accordance with the disclosed embodiments.
  • the best polymerization result via printing occurred with 60 mg/ml fibronigen, 50 unit/ml thrombin, and 80 mM CaCl 2 - Minimum deformations and diffusions of printed fibrin pattern were observed at these concentrations.
  • MCDB 131 endothelial cells culture media
  • thrombin solution thrombin solution
  • fibrinogen solution matched osmolality is required for endothelial cells culture media (MCDB 131), thrombin solution, and fibrinogen solution.
  • Serum free MCDB 131 media, 1* DPBS, and distilled water were used to make thrombin and fibrinogen solutions for osmolality study.
  • the osmolality of different solutions was tested using an Advanced Micro osmometer.
  • Endothelial cells form the inner lining of the whole cardiovascular system and have a remarkable capacity to adjust their number and arrangement to suit local requirements. Almost all tissues depend on a blood supply and a blood supply depends on endothelial cells. Endothelial cells are the only cells to form capillaries, creating an adaptable life-support system spreading into almost every region of the body. Endothelial cells extending and remodeling the network of blood vessels make it possible for tissue growth and repair (angiogenesis).
  • HP ® Deskjet 500 printer and HP ® 51626A cartridges were modified to print fabricate fibrin channels.
  • the modified inkjet printer was UV sterilized overnight and modified ink cartridges were sprayed using 100% ethanol before using.
  • Thrombin solution was served as bio-ink and fibrinogen was substrate on a microscope cover slip (bio-paper). After printing, the printed samples were incubated at 37°C for 5-10 min until white printed scaffolds were observed.
  • HMVEC 251 was cultured in MCDB 131 media supplemented with FBS, L- glutamine, hydrocortisone, HEGF, and heparin.
  • the culture condition was standard at 37°C with 5% CO2 for 10 days before passaging. Culture media was changed every two days. During passaging, cell suspension was centrifuged at 1000 rpm for 5 min. The supernatant was aspirated and the cell pellet was re-suspended using 1 ml 1* DPBS.
  • the bio-ink was made by mixing the same volume of cell suspension and 100 unit/ml thrombin with 160 mM Ca 2+ in 1* DPBS. The final condition of bio-ink has 1-8 million cells/ml HMVEC, 50 unit/ml thrombin, and 80 mM Ca 2+ in 1x DPBS.
  • the biological ink mentioned above was added into a sterile modified HP ® 51626A cartridge. 60 mg/ml fibrinogen solution was served as bio-paper on a microscope cover slip. UV sterilized modified HP ® Deskjet 500 printer was used to print patterns. Cells in bio-ink were simultaneously deposited and aligned into the channel during the fibrin channel formation (as illustrated in FIG. 4). The printed patterns were incubated for 15-20 min at 37°C for the printed cell attachment as well as fibrin polymerization. After that, a few drops of MCDB 131 media were carefully added onto the printed patterns for nutrition and moisture. The patterns were then cultured at 37°C with 5% CO2 for up to 21 days. Media was changed every two days during the culture.
  • Live/Dead Viability/Cytotoxicity Kit was used to stain the printed HMVEC 251 in fibrin scaffolds.
  • Printed samples were analyzed after 24 hours, 7 days, 14 days, and 21 days of printing to show the progress of the cell proliferation in the fabricated microvasculature.
  • the staining solution was made by adding 5 ⁇ 4 mM calcein AM and 20 ⁇ 2 mM ethidium homodimer-1 into 10 ml 1x DPBS solution. The samples were incubated in the staining solution for 30-45 min at room temperature in the dark.
  • Zeiss ® Axiovert S100 UV microscope and Zeiss ® LSM 510 confocal microscope were used to observe the 2D and 3D fluorescent images.
  • Printed fibrin scaffold with minimum thrombin diffusion and scaffold deformations were obtained using the concentrations of 50 unit/ml thrombin, 80 mM CaCl 2 , and 60 mg/ml fibrinogen (as illustrated in FIG. 5).
  • Osmolality of thrombin solution of 50 unit/ml thrombin and 80 mM Ca 2+ in 1* DPBS was 359 mOsm.
  • Osmolality of 60 mg/ml fibrinogen in distilled water was 341 mOsm.
  • the osmolality of MCDB 131 culture media was 348 mOsm. The osmolalities of these solutions were similar. After fibrin scaffold was printed, only minor deformations of the scaffold structure in the HMVEC 251 culture media were noticed.
  • FIG. 6 illustrates pictorial illustrations 350, 355, 360 of printed fibrin scaffold using a modified HP ® Deskjet 500 thermal inkjet printer, in accordance with the disclosed embodiments.
  • the grid structure in illustration 350 illustrates the grid structure at a 1mm magnification.
  • the grid structure in illustration 355 illustrates the grid structure at a 100 ⁇ m magnification.
  • the grid structure in illustration 360 illustrates the grid structure at a 25 ⁇ m magnification.
  • the structural integrity of the printed fibrin scaffold remains sound after the print. Only minor deformations were noticed at the y- axis; the arrows 356, 357 in illustration 355 indicate these minor deformations.
  • the higher magnified images in 355 and 360 show that the fibrin fiber structures were well aligned and straight, appropriate for cell seeding and microvasculature fabrication.
  • the burst pressure of the printed fibrin fiber was 2955 mm Hg.
  • the mechanical properties of the printed fibrin fibers are sound.
  • FIG. 7 illustrates pictorial illustrations 400, 410 of scanning electron microscope images of printed fibrin fiber, in accordance with the disclosed embodiments.
  • the microstructure of printed fibrin fibers was examined using a scanning electron microscope.
  • the printed fibrin fibers were first dried in 100% ethanol at 4°C overnight then were critically dried under vacuum and CO2- After that, the dried fibers were cut through the middle to observe the possible channel structure on the cross section surface.
  • the hole shows the channel opening of the printed hollow fibrin fiber for cell seeding and proliferation.
  • the fixed fibers were sputter-coated with a thin layer of Chromium using the Hummer 6.2 sputter coater in 100 m Torr vacuum argon environment for a 5 min period and 10 mA of current. SEM images were taken using the Hitachi ® SEM mentioned above at a 5 kV accelerating voltage. Nano-sized fibers on the printed fibrin scaffold surface which can help the cells to attached and proliferate, as illustrated in 410.
  • FIG. 8 illustrates pictorial illustrations 450, 460, 470, 480 of magnified, printed human microvasculature from a printed pattern 451, in accordance with the disclosed embodiments.
  • Images 450, 460, 470, 480 are taken from different parts of the printed pattern 451 which showed the progress of printed HMVEC 251 proliferation.
  • Illustration 450 illustrates that the printed cells aligned well after 24 hours and were ready to proliferate. This also shows the ability of the modified thermal inkjet printers to deposit the cells accurately with digital control. After 7 days, printed HMVEC 251 started to proliferate following the printed pattern 451 which is shown in 460 and 470. The deposited cells were also trying to contact and connect each other.
  • 480 When cultured for 21 days, 480 illustrates the printed cells aligned themselves in the fibrin channel and also proliferated to form a confluent lining. At the right end of the printed microvasculature, the proliferated cells were trying to reach the other deposited cells and connect with them. This shows the potential of using the modified thermal inkjet printers to simultaneously deposit fibrin and HMVEC 251 for human microvasculature fabrication.
  • FIG. 9 illustrates pictorial illustrations 500, 510, 520 of the channel structure of printed microvasculature cultured for 21 days, in accordance with the disclosed embodiments.
  • Pictorial illustrations 500, 510, and 520 illustrate the tubular structure of the printed human microvasculature cultured for 21 days.
  • Illustration 500 shows the cells aligned inside the fibrin channel. Fluorescent stained printed cells aligned inside the fibrin scaffold.
  • Illustration 510 is a DIC image of the printed fibrin fiber.
  • Illustration 520 is a confocal series image at the z-axis and was taken at 5 ⁇ intervals of the printed structure. These series images at the z-axis were rendered into a 3D image using ImageJ to show the channel structure.
  • the rendered 3D image was turned around along x-axis to show the 3D structure of the printed structure. Twelve consequent images were taken from the 3D movie as shown in illustration 520.
  • the endothelial cells tended to form channel or tubular structure as a functionality of angiogenesis.
  • the edge of the channel structure is clearly indicated by white arrows in illustration 520.
  • the proliferated endothelial cells were functional and attempting to seal inside of the fibrin channel and form a tubular structure. It also shows that simultaneous deposition of endothelial cells and fibrin gel using thermal inkjet printing technology can be used for human microvasculature fabrication.
  • FIG. 10 illustrates pictorial illustrations of the integrity of the printed human microvasculature, in accordance with the disclosed embodiments.
  • Illustration 550 illustrates a printed perpendicular microvasculature cultured for 14 days. The printed perpendicular microvasculature was cultured for 14 days. Defects were found in the structure indicating the cells required more time to proliferate into confluence.
  • Illustration 560 illustrates the integrity of the printed structure stained using Texas Red conjugated dextran molecules with 3000 MW. Some integrity was demonstrated by the expulsion of red fluorescent dextran molecules from the printed structure.
  • Illustration 570 illustrates a printed ring shaped microvasculature cultured for 21 days. Illustration 580 illustrates the integrity of the printed structure using the same dextran molecules.
  • human microvascular endothelial cells can be simultaneously deposited along with the appropriate biomaterials (i.e., fibrin) for microvasculature fabrication using the modified thermal Inkjet printers.
  • the printed endothelial cells proliferate to form a confluent lining along with the fibrin scaffold after 21 days of culture.
  • the rendered 3D channel structure through the series confocal images at the z-axis shows the functionality of the printed human microvasculature.
  • Printed endothelial cells proliferate to form a tubular structure and seal inside the fibrin channel.
  • the fabricated microvasculature also shows some integrity after being cultured for 14 days. Much better integrity is observed from the printed structure cultured for 21 days.
  • FIG. 11 illustrates a pictorial illustration 600 of an intraoperative adipose tissue engineering device 601, in accordance with the disclosed embodiments.
  • the device 601 can be used to fabricate adipose tissue constructs 602 from cells that were freshly obtained during lipoplasty and print viable cells in three dimensions.
  • the printer interface 603, which is preferably a graphical user interface (GUI), can serve to display cell printing options, cell printing results, whereupon a user may supply additional inputs or terminate a particular session.
  • GUI graphical user interface
  • the device 601 is capable of generating hollow fibrin tubes that are lined with endothelial cells, surrounded by a matrix of other adipose-derived cells.
  • Adipose tissue has not been engineered with endothelial-lined vessels.
  • the device can layer these tubes arbitrarily in three dimensions within the cell/fibrinogen/collagen matrix.
  • a precise three-dimensional reconstruction of adipose-like tissue with endothelial cell tubes can then be formed.
  • the tissue can be used in tissue augmentation from cancer resections or to fill other defects where adipose tissue is desired.
  • the device 601 uses image- based control of the size and thickness of the reconstructed tissue and can thus be interfaced with most three dimensional image modeling software. Processing and adipose reconstruction will be done intraoperatively with the device never leaving the surgical room, for example.
  • the integration with existing tissue may be quicker, thus the survival rate may be improved. If low survival rates from partial necrosis can be overcome, the method of soft tissue augmentation can be performed without detectable scarring on the donor or recipient site and without complications associated with foreign materials. Thus, if the clinical efficacy and safety of the procedure can be improved, the disclosed embodiments are a strong cosmetic and reconstructive tool for soft tissue augmentation.
  • the disclosed embodiments can include, for example: vascularized mesh to support growth of multiple types of cells; vasculature comprising at least one of or a combination of cells (e.g., fibroblasts, keratinocytes, melanocytes, etc.); vascularization with adipose; cells can originate from allogeneic or autologous sources; printing a bi- layer (i.e., multilayer) skin construct, with the layers having different densities of cell types such as, for example, a dermal layer and an epidermal layer; building an "exact" size match (i.e., all three dimensions) wound dressing or tissue replacement construct based on a "photo" or other image such as MRI or scan; utilizing software and printing to produce the matched wound dressing or tissue replacement construct; and temperature control of the printer stage and cartridge.
  • a bi- layer i.e., multilayer
  • wound dressing or tissue replacement construct based on a "photo" or other image such as MRI or scan
  • Embodiments include, for example, the treatment of lipoaspirates to separate CD-31 positive endothelial-like cells form a mixture of adipose cells, adipose tissue- derived stem cells, and other adipose tissue-derived cells, such as interstitial fibroblasts.
  • the endothelial-like cells can be mixed with buffer and thrombin and added to the device.
  • the remaining cells can be mixed with buffer, fibrinogen, and collagen.
  • the method can include steps for: rendering biological ink via a rendering device; rendering a material along with the biological ink via the rendering device; and aligning the rendered biological ink and the rendered material into fibrin channels wherein the biological ink proliferates in a presence of the rendered material to form the microvasculature.
  • the biological ink comprises human microvascular endothelial cells and fibrin and the material comprises at least one of living cells, a nutrient, a growth factors, a therapeutic drug.
  • the rendering device comprises an ink jet printer, wherein a printer cartridge of the ink jet printer is modified to accommodate the biological ink and the material.
  • rendering the material along with the biological ink via the rendering device can further include a step for simultaneously depositing at least one of living cells, a nutrient, a growth factor, and a therapeutic drug along with the human microvascular endothelial cells and fibrin via the rendering device.
  • the aligning the human microvascular endothelial cells and the fibrin inside fibrin channels further includes a step for utilizing drop-on-demand polymerization wherein the human microvascular endothelial cells and fibrin proliferate, and wherein the microvasculature is functional and comprises a confluent lining and a three-dimensional cellular scaffold.
  • the method includes a step for heating the human microvascular endothelial cells, the fibrin, and the material to a preferable temperature between four degrees Celsius and thirty degrees Celsius above ambient temperature during rendering, wherein energy supplied during the rendering is transferred into kinetic energy to heat the human microvascular endothelial cells, the fibrin, and the material.
  • the method includes steps for: supporting growth of multiple types of cells via a vasculature, the vasculature comprising at least one fibroblasts, interstitial fibroblasts, keratinocytes, melanocytes, adipose cells, adipose tissue-derived stem cells, cells from allogeneic or autologous sources; rendering a multiple-layer tissue construct, wherein the multiple-layer tissue construct comprises a plurality of densities and cell types, and wherein the multiple-layer tissue construct comprises at least one of a skin construct, an adipose construct, and a combination skin construct and adipose construct; and rendering at least one of a size match wound dressing, tissue replacement construct, and skin graft.
  • a system for rendering a microvasculature can include a processor, a data bus coupled to the processor; and a computer-usable tangible storage device storing computer program code, the computer program code comprising program instructions executable by the processor for rendering a microvasculature.
  • the program instructions can include: program instructions to render biological ink via a rendering device; program instructions to render a material along with the biological ink via the rendering device; and program instructions to align the rendered biological ink and the rendered material into fibrin channels wherein the biological ink proliferates in a presence of the rendered material to form the microvasculature.
  • the biological ink comprises human microvascular endothelial cells and fibrin.
  • the rendering device comprises an ink jet printer, wherein a printer cartridge of the ink jet printer is modified to accommodate the biological ink and the material.
  • the material comprises at least one of living cells, a nutrient, a growth factors, a therapeutic drug.
  • the program instruction to render the material along with the biological ink via the rendering device further comprises program instructions to simultaneously deposit at least one of living cells, a nutrient, a growth factor, and a therapeutic drug along with the human microvascular endothelial cells and fibrin via the rendering device.
  • the program instruction to align the human microvascular endothelial cells and the fibrin inside fibrin channels further comprises program instructions to utilize drop-on-demand polymerization wherein the human microvascular endothelial cells and fibrin proliferate, and wherein the microvasculature is functional and comprises a confluent lining and a three- dimensional cellular scaffold.
  • the system includes program instructions to heat the human microvascular endothelial cells, the fibrin, and the material to a preferable temperature between four degrees Celsius and thirty degrees Celsius above ambient temperature during rendering, wherein energy supplied during the rendering is transferred into kinetic energy to heat the human microvascular endothelial cells, the fibrin, and the material.
  • the system includes: program instructions to support growth of multiple types of cells via a vasculature, the vasculature comprising at least one fibroblasts, interstitial fibroblasts, keratinocytes, melanocytes, adipose cells, adipose tissue-derived stem cells, cells from allogeneic or autologous sources; program instructions to render a multiple-layer tissue construct, wherein the multiple-layer tissue construct comprises a plurality of densities and cell types, and wherein the multiple-layer tissue construct comprises at least one of a skin construct, an adipose construct, and a combination skin construct and adipose construct; and program instructions to render at least one of a size match wound dressing, tissue replacement construct, and skin graft.
  • a computer-usable tangible storage device storing computer program code for rendering a microvasculature.
  • the computer program code comprising program instructions executable by a processor, includes computer program instructions for: program instructions to render biological ink via a rendering device; program instructions to render a material along with the biological ink via the rendering device; and program instructions to align the rendered biological ink and the rendered material into fibrin channels wherein the biological ink proliferates in a presence of the rendered material to form the microvasculature.
  • the program instruction to render said material along with the biological ink via the rendering device further comprises program instructions to simultaneously deposit at least one of living cells, a nutrient, a growth factor, and a therapeutic drug along with human microvascular endothelial cells and fibrin via the rendering device.
  • the program instructions further include program instructions to align the human microvascular endothelial cells and the fibrin inside fibrin channels further comprises program instructions to utilize drop-on-demand polymerization wherein the human microvascular endothelial cells and fibrin proliferate, and wherein the microvasculature is functional and comprises a confluent lining and a three-dimensional cellular scaffold.
  • program instructions further include program instructions to heat the human microvascular endothelial cells, the fibrin, and the material to a preferable temperature between four degrees Celsius and thirty degrees Celsius above ambient temperature during rendering, wherein energy supplied during the rendering is transferred into kinetic energy to heat the human microvascular endothelial cells, the fibrin, and the material.
  • the program instructions include: program instructions to support growth of multiple types of cells via a vasculature, the vasculature comprising at least one fibroblasts, interstitial fibroblasts, keratinocytes, melanocytes, adipose cells, adipose tissue-derived stem cells, cells from allogeneic or autologous sources; program instructions to render a multiple-layer tissue construct, wherein the multiple-layer tissue construct comprises a plurality of densities and cell types, and wherein the multiple-layer tissue construct comprises at least one of a skin construct, an adipose construct, and a combination skin construct and adipose construct; and program instructions to render at least one of a size match wound dressing, tissue replacement construct, and skin graft.
  • an engineered adipose tissue graft comprises: a plurality of cells and biomaterials in an engineered fibrin scaffold; tube-like channels within the cellular scaffold; and a plurality of microvascular channels within the fibrin for vascularization of the engineered adipose tissue graft.
  • the plurality of cells comprises at least one of fibroblasts, interstitial fibroblasts, keratinocytes, melanocytes, adipose cells, adipose tissue-derived stem cells, cells from an allogenic source, and cells from a autologous source.
  • the biomaterials comprise at least one of living cells, a nutrient, a growth factor, a therapeutic drug.
  • the vasculature comprises at least one of fibroblasts, interstitial fibroblasts, keratinocytes, melanocytes, adipose cells, adipose tissue-derived stem cells, cells from an allogenic source, and cells from a autologous source.
  • the plurality of microvascular channels are interconnected and of dimensions less than 200 micrometers in diameter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Optics & Photonics (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

L'invention concerne un procédé d'impression à jet d'encre, un système et un dispositif de stockage tangible utilisable par le biais d'un ordinateur pour imprimer des cellules et des biomatériaux pour des échafaudages cellulaires tridimensionnels et des greffes de peau génétiquement modifiées. Le procédé dépose simultanément des cellules vivantes, des nutriments, des facteurs de croissance, des médicaments thérapeutiques ainsi que des échafaudages de biomatériaux au bon moment et au bon endroit. Cette technologie peut également être utilisée pour la fabrication de microvasculature en utilisant des cellules endothéliales microvasculaires humaines appropriées et de la fibrine pour former la microvasculature. Lorsque l'on imprime des cellules endothéliales microvasculaires humaines conjointement avec de la fibrine, les cellules s'alignent à l'intérieur des canaux et prolifèrent pour former des muqueuses confluentes. La structure tubulaire 3D est également observée dans les motifs imprimés. L'impression simultanée de matériaux biologiques pour former un échafaudage cellulaire tridimensionnel favorise la prolifération de cellules endothéliales microvasculaires humaines et la formation de microvasculature.
PCT/US2013/025938 2012-02-14 2013-02-13 Dispositif de génie tissulaire et construction de derme vascularisé WO2013123049A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13749912.5A EP2814529A4 (fr) 2012-02-14 2013-02-13 Dispositif de génie tissulaire et construction de derme vascularisé
CA2864665A CA2864665A1 (fr) 2012-02-14 2013-02-13 Dispositif de genie tissulaire et construction de derme vascularise
AU2013221660A AU2013221660A1 (en) 2012-02-14 2013-02-13 Tissue engineering device and construction of vascularized dermis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598683P 2012-02-14 2012-02-14
US61/598,683 2012-02-14

Publications (1)

Publication Number Publication Date
WO2013123049A1 true WO2013123049A1 (fr) 2013-08-22

Family

ID=48984658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/025938 WO2013123049A1 (fr) 2012-02-14 2013-02-13 Dispositif de génie tissulaire et construction de derme vascularisé

Country Status (4)

Country Link
EP (1) EP2814529A4 (fr)
AU (1) AU2013221660A1 (fr)
CA (1) CA2864665A1 (fr)
WO (1) WO2013123049A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106488A1 (fr) * 2014-01-20 2015-07-23 清华大学 Structure de tissu vascularisé avec passage microfluidique et son procédé de préparation
WO2017143356A1 (fr) * 2016-01-25 2017-08-24 Sunp Biotech, Llc Module à haute température pour système de dépôt d'imprimante biologique 3d
EP3215603A4 (fr) * 2014-11-05 2018-05-30 Organovo, Inc. Tissus cutanés tridimensionnels manipulés, ensembles correspondants et leurs procédés de production
CN111132840A (zh) * 2017-05-25 2020-05-08 汀布特Ip有限公司 包括双臂机构的无菌打印机系统
US11051509B2 (en) 2016-11-22 2021-07-06 William Lafayette Mondy Method and apparatus for keeping artificially created tissues alive
CN113604421A (zh) * 2021-08-06 2021-11-05 苏州瑞华骨科医院有限公司 基于3d打印的血管化双层工程皮肤及其制备方法
US11305480B2 (en) 2016-01-28 2022-04-19 3D Systems, Inc. Methods and apparatus for 3D printed hydrogel materials
US11850330B2 (en) 2016-11-10 2023-12-26 Organovo, Inc. Bioprinted hair follicles and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU502391B1 (en) 2022-06-28 2024-01-09 Univerza V Mariboru A complex in vitro model of human skin, a process for preparation and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110250688A1 (en) 2008-11-24 2011-10-13 Immunotrex Corporation Three Dimensional Tissue Generation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110250688A1 (en) 2008-11-24 2011-10-13 Immunotrex Corporation Three Dimensional Tissue Generation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CUI ET AL.: "Human microvasculature fabrication using thermal inkjet printing technology", BIOMATERIALS, vol. 30, no. 31, 19 August 2009 (2009-08-19), pages 6221 - 6227, XP026574960 *
CUI ET AL.: "Human microvasculature fabrication using thermal inkjet printing technology", BIOMATERIALS, vol. 30, no. 31, 2009, pages 6221 - 6227
GRIFFITH ET AL.: "Diffusion limits of an in vitro thick prevascularized tissue", TISSUE ENGINEERING, vol. 11, no. 1/2, 28 February 2005 (2005-02-28), pages 257 - 266, XP055161801 *
MIRONOV ET AL.: "Organ Printing : Tissue spheroids as building blocks", BIOMATERIAL, vol. 30, no. 12, 2009, pages 2164 - 2174
MIRONOV ET AL.: "Organ printing: computer-aided jet-based 3D tissue engineering", TRENDS IN BIOTECHNOLOGY, vol. 21, no. 4, April 2003 (2003-04-01), pages 157 - 161, XP004417389 *
PAPAVASILIOU ET AL.: "Strategies for vascularization of polymer scaffolds", JOURNAL OF INVESTIGATIVE MEDICINE, vol. 58, no. 7, October 2010 (2010-10-01), pages 838 - 844, XP055161805 *
See also references of EP2814529A4 *
SUN ET AL.: "Computer-aided tissue engineering: overview, scope and challenges", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 39, no. 1, 2004, pages 29 - 47, XP009117444 *
WUST ET AL.: "Controlled positioning of cells in biomaterials-approaches towards 3D tissue printing", JOURNAL OF FUNCTIONAL BIOMATERIALS, vol. 2, no. 3, 2011, pages 119 - 154
WUST ET AL.: "Controlled positioning of cells in biomaterials-approaches towards 3d tissue printing", JOURNAL OF FUNCTIONAL BIOMATERIALS, vol. 2, no. 3, 4 August 2011 (2011-08-04), pages 119 - 154, XP055161816 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106488A1 (fr) * 2014-01-20 2015-07-23 清华大学 Structure de tissu vascularisé avec passage microfluidique et son procédé de préparation
EP3215603A4 (fr) * 2014-11-05 2018-05-30 Organovo, Inc. Tissus cutanés tridimensionnels manipulés, ensembles correspondants et leurs procédés de production
US11529436B2 (en) 2014-11-05 2022-12-20 Organovo, Inc. Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same
WO2017143356A1 (fr) * 2016-01-25 2017-08-24 Sunp Biotech, Llc Module à haute température pour système de dépôt d'imprimante biologique 3d
US11305480B2 (en) 2016-01-28 2022-04-19 3D Systems, Inc. Methods and apparatus for 3D printed hydrogel materials
US11850330B2 (en) 2016-11-10 2023-12-26 Organovo, Inc. Bioprinted hair follicles and uses thereof
US11051509B2 (en) 2016-11-22 2021-07-06 William Lafayette Mondy Method and apparatus for keeping artificially created tissues alive
CN111132840A (zh) * 2017-05-25 2020-05-08 汀布特Ip有限公司 包括双臂机构的无菌打印机系统
CN111132840B (zh) * 2017-05-25 2023-01-13 汀布特Ip有限公司 包括双臂机构的无菌打印机系统
CN113604421A (zh) * 2021-08-06 2021-11-05 苏州瑞华骨科医院有限公司 基于3d打印的血管化双层工程皮肤及其制备方法
CN113604421B (zh) * 2021-08-06 2023-09-19 苏州瑞华骨科医院有限公司 基于3d打印的血管化双层工程皮肤及其制备方法

Also Published As

Publication number Publication date
EP2814529A1 (fr) 2014-12-24
EP2814529A4 (fr) 2015-12-02
CA2864665A1 (fr) 2013-08-22
AU2013221660A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
US10195644B2 (en) Tissue engineering device and construction of vascularized dermis
WO2013123049A1 (fr) Dispositif de génie tissulaire et construction de derme vascularisé
Cui et al. Human microvasculature fabrication using thermal inkjet printing technology
Richard et al. The emerging role of microfluidics in multi-material 3D bioprinting
Moldovan et al. Principles of the Kenzan method for robotic cell spheroid-based three-dimensional bioprinting
Seol et al. Bioprinting technology and its applications
Millik et al. 3D printed coaxial nozzles for the extrusion of hydrogel tubes toward modeling vascular endothelium
Tan et al. Applications of 3D bioprinting in tissue engineering: advantages, deficiencies, improvements, and future perspectives
Chang et al. Direct‐write bioprinting three‐dimensional biohybrid systems for future regenerative therapies
Yang et al. Emerging 3D bioprinting applications in plastic surgery
US9301925B2 (en) Inkjet printing of tissues and cells
Savoji et al. 3D printing of vascular tubes using bioelastomer prepolymers by freeform reversible embedding
Correia Carreira et al. 3D bioprinting: the emergence of programmable biodesign
AU2015101219A4 (en) Method for preparing cell-laden 3D scaffolds and application
Ke et al. Current challenges of bioprinted tissues toward clinical translation
Joshi et al. Strategies to promote vascularization in 3D printed tissue scaffolds: trends and challenges
Tripathi et al. 3D bioprinting and its innovative approach for biomedical applications
Zhang et al. Advances in 3D skin bioprinting for wound healing and disease modeling
Iyer et al. Biofabrication enables efficient interrogation and optimization of sequential culture of endothelial cells, fibroblasts and cardiomyocytes for formation of vascular cords in cardiac tissue engineering
Zhang et al. Three-dimensional bioprinting is not only about cell-laden structures
Kumar et al. 3D bioprinting of nature-inspired hydrogel inks based on synthetic polymers
Jafari et al. Latest advances in 3D bioprinting of cardiac tissues
Ciocci et al. Scaffold-in-scaffold potential to induce growth and differentiation of cardiac progenitor cells
Campbell et al. Multimaterial and multiscale three-dimensional bioprinter
Assad et al. Recent developments in 3D bio-printing and its biomedical applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13749912

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2864665

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013221660

Country of ref document: AU

Date of ref document: 20130213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013749912

Country of ref document: EP